Drugs

The Future Potential of Eicosanoids and Their Inhibitors in Paediatric Practice
pp. 169-176(8)
Author: Shimizu T.

Management of the Hypertensive Patient Who Smokes
pp. 177-187(11)
Authors: Pardell H.; Tresserras R.; Saltó E.; Armario P.; Hernández R.

Drug Treatment of Hypertension Complicating Diabetes Mellitus
pp. 189-202(14)
Authors: MacLeod M.J.; McLay J.

Genetics of Hypertension: Therapeutic Implications
pp. 203-214(12)
Authors: O’Byrne S.; Caulfield M.

Current Drug Therapy Recommendations for the Treatment of Attention Deficit Hyperactivity Disorder
pp. 215-223(9)
Authors: Cyr M.; Brown C.S.

Current Guidelines for the Drug Treatment of Ankylosing Spondylitis
pp. 225-240(16)
Authors: Toussirot E.; Wendling D.

Orlistat
pp. 241-249(9)
Authors: McNeely W.; Benfield P.

Orlistat: A Viewpoint by Madeleine L. Drent
pp. 250-250(1)
Author: Drent M.L.

Orlistat: A Viewpoint by F. Xavier Pi-Sunyer
pp. 250-250(1)
Author: Pi-Sunyer F.X.

Montelukast
pp. 251-256(6)
Authors: Markham A.; Faulds D.

Montelukast: A Viewpoint by Romain A. Pauwels
pp. 257-257(1)
Author: Pauwels R.A.

Montelukast: A Viewpoint by Carl Burgess and Julian Crane
pp. 257-257(1)
Authors: Burgess C.; Crane J.

Enoxaparin: A Review of its Clinical Potential in the Management of Coronary Artery Disease
pp. 259-272(14)
Authors: Noble S.; Spencer C.M.

Azithromycin: A Review of its Use in Paediatric Infectious Diseases
pp. 273-297(25)
Authors: Langtry H.D.; Balfour J.A.